Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01174914
Recruitment Status : Completed
First Posted : August 4, 2010
Last Update Posted : August 4, 2010
Information provided by:
The Ojai Foundation

Brief Summary:
In the vast majority of those infected with HIV virus who are untreated, there is deterioration in immune health over a period of months or years inevitably leading to full-blown AIDS and demise. Treatment with ARV's stop or slow down this deterioration if started before a certain degree of progression occurs and has saved millions of lives. The investigators' study hypothesis is that effectiveness of a very low dose of an FDA-approved medication, naltrexone hydrochloride, (Low-Dose Naltrexone, or LDN) will compare favorably to ARV's to prevent progression of HIV+ toward immune deterioration and full-blown AIDS.

Condition or disease Intervention/treatment Phase
HIV Seropositivity Other: ARV's + Placebo Drug: Naltrexone Drug: Naltrexone + ARV's Phase 2

Detailed Description:
The LDN (low-dose naltrexone) vs ARV (anti-retroviral drugs) Effectiveness Study in Mali sponsored by The Ojai Foundation in California-USA is a clinical research study endorsed and approved by the Malian Government. Naltrexone hydrochloride is a generic, FDA-approved since 1998 drug, an opioid antagonist that has clinically shown immune enhancing/modulating qualities in very low dosage and may offer an alternative to ARV drugs that is effective, non-toxic, easily available, inexpensive, with simple once-daily at bedtime administration. LDN capsules must be created by compounding pharmacists to get these ultra-small doses. Due to toxicity of current ARV drugs and need for special medical management young HIV infected children are largely neglected particularly in developing countries; LDN can also be made available in a transdermal cream for infants and children who are HIV infected.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 171 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Phase 2 Comparison of Low-Dose Naltrexone vs ARV Effectiveness in HIV+ Progression
Study Start Date : March 2008
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Naltrexone Low-dose 3mg capsule
Each person in this arm 1 of the study had never received any ARV drugs and in this study received only one Low-Dose Naltrexone 3mg capsule nightly for 9 months (no placebo).
Drug: Naltrexone
Naltrexone, Low-Dose (3mg) given once daily at bedtime for 9 months

Active Comparator: Naltrexone Low Dose + ARVs
In this Arm 3, Patients were on ARV's plus being given Naltrexone Low-Dose (3mg) once daily at bedtime for 9 months.
Drug: Naltrexone + ARV's
Patients were given standard ARV's plus Naltrexone (Low Dose) 3mg nightly.
Other Names:
  • Azidothimidine + lamivudine + nevirapine Or
  • Stavudine + lamivudine + nevirapine (TRIOMUNE)Or
  • Azidothimidine + lamivudine + efavirenz Or
  • Azidothimidine + lamivudine + lopinavir/r Or
  • Emtricitabine + tenofovir + efavirenz

Placebo Comparator: ARV's (continued,standard) plus Placebo
In this arm 2, patients were started or continued on their standard ARV drugs plus placebo capsule once daily at bedtime; in the 2nd and 3rd arms patients did not know whether they were taking Low-Dose Naltrexone or a placebo.
Other: ARV's + Placebo
Patients continued ARV's plus a placebo nightly for 9 months
Other Names:
  • Azidothimidine + lamivudine + nevirapine Or
  • Stavudine + lamivudine + nevirapine (TRIOMUNE)Or
  • Azidothimidine + lamivudine + efavirenz Or
  • Azidothimidine + lamivudine + lopinavir/r Or
  • Emtricitabine + tenofovir + efavirenz

Primary Outcome Measures :
  1. CD4+ percentage (change in HIV-1 seropositive patients) [ Time Frame: 9 MONTHS ]
    HIV+ patients with CD4+ count over 350 had their CD4 count/percentage measured at beginning, at 15 days, at 1 month, 3 months, 6 months and 9 months (end).

Secondary Outcome Measures :
  1. Clinical assessment of evidence of AIDS or other serious illness [ Time Frame: 9 MONTHS ]
    HIV+ patients with CD4 counts over 200 on ARV drugs were given clinical assessment and testing for evidence of opportunistic infections (AIDS) at each visit for blood testing: (Beginning, 15 days, 1 month, 3 months, 6 months, & 9 months (end).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HIV-1 infected
  • CD4 count over 350 (arm 1/group 1)
  • CD4 count over 200 and on ARV's (arms 2,3/groups 2,3)
  • Age between 18 & 60
  • Males or females

Exclusion criteria:

  • HIV-1 seronegative
  • HIV-2 infected
  • CD4 count lower than 200
  • patients under age 18
  • Those refusing to be in study
  • Pregnant or breast-feeding women
  • Patients under immuno-suppressor therapy
  • Those with renal or hepatic dysfunction
  • Malaria or tuberculosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01174914

Layout table for location information
University Hospital of Point G
Bamako, Mali, BP0 Box 333
Sponsors and Collaborators
The Ojai Foundation
Layout table for investigator information
Principal Investigator: Abdel K Traore, MD Professor, Bamako University School of Medicine
Layout table for additonal information
Responsible Party: Abdel Kader Traore, MD, PI, Professor Bamako University School of Medicine, Pharmacy and Odontostomatology, University of Bamako (Mali) Medical School Identifier: NCT01174914    
Other Study ID Numbers: TOFLDNMALIHIVb
First Posted: August 4, 2010    Key Record Dates
Last Update Posted: August 4, 2010
Last Verified: August 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Seropositivity
HIV Infections
Blood-Borne Infections
Communicable Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Genital Diseases
Urogenital Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Stavudine, lamivudine, nevirapine drug combination
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action